Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471919 | 0.84 | MEP1B (0.50) | KDM4EALDH1A1SMN1; SMN2NOS1NOS3 | |
| SCHEMBL8340724 | 0.84 | MEP1B (0.50) | KDM4EALDH1A1SMN1; SMN2NOS1NOS3 | |
| SCHEMBL11167304 | 0.83 | NOS1 (0.43) | DHFRKDM4EALDH1A1NOS1NOS3 | |
| SCHEMBL2903748 | 0.83 | CHRM2 (0.68) | DHFRKDM4ENSD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL12124936 | 0.82 | GRM2 (0.40) | KDM4EALDH1A1NOS1NOS3PRMT6 | |
| SCHEMBL17788596 | 0.81 | DHFR (0.49) | DHFRKDM4ENSD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2938384 | 0.80 | NPC1 (0.56) | KDM4ENSD2ALDH1A1SMN1; SMN2HDAC4 | |
| SCHEMBL5537784 | 0.80 | HDAC4 (0.44) | DHFRKDM4ENSD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5537789 | 0.80 | ADH1B (0.49) | DHFRKDM4ENSD2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1908523 | 0.79 | MAPK1 (0.49) | DHFRKDM4ENSD2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20120058473-A1 | Molecular Adaptors for Dye Conjugates | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-5840725-A | Substituted oximes, hydrazones and olefins as neurokinin antagonists | SCHERING CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5696267-A | ANTIHISTAMINES; ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | DHFR 1768/4885KDM4E 786/4885NSD2 2809/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | DHFR 561/4885KDM4E 1199/4885NSD2 1811/4885 |
| US-20120058473-A1 | Molecular Adaptors for Dye Conjugates | ALKBH1, ALKBH5, ALKBH3 | DHFR 1948/4885KDM4E 220/4885NSD2 1886/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | DHFR 2779/4885KDM4E 1067/4885NSD2 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.